Jubilant Pharmova Ltd. - Research Center
530019 JUBLPHARMA Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sales | 810.12 | 87.75 | 2,709.50 | 3,139.90 | 3,438.61 |
| Operating profit | 3.22 | -6.78 | 427.06 | 370.91 | 320.87 |
| Interest | 18.52 | 30.59 | 101.80 | 136.20 | 128.96 |
| Gross profit | 122.59 | 88.50 | 373.14 | 407.94 | 269.91 |
| EPS (Rs) | 3.13 | 4.93 | 13.46 | 20.16 | 9.27 |
Annual
results in details
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Other income | 137.89 | 125.87 | 47.88 | 173.23 | 78.00 |
| Stock adjustment | 3.45 | - | 55.21 | -108.32 | 46.74 |
| Raw material | 396.30 | - | 1,328.92 | 1,683.29 | 1,874.60 |
| Power and fuel | - | - | 280.40 | 369.20 | 358.28 |
| Employee expenses | 167.27 | 49.21 | 220.67 | 264.90 | 265.71 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 239.88 | 45.32 | 397.24 | 559.92 | 572.41 |
| Provisions made | - | - | - | - | - |
| Depreciation | 43.25 | 6.25 | 99.97 | 107.40 | 86.48 |
| Taxation | 29.46 | 3.75 | 58.69 | -22.30 | 35.80 |
| Net profit / loss | 49.88 | 78.50 | 214.48 | 321.14 | 147.63 |
| Extra ordinary item | - | - | - | -1.70 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 0.40 | -7.73 | 15.76 | 11.81 | 9.33 |
| GPM (%) | 12.93 | 41.43 | 13.53 | 12.31 | 7.68 |
| NPM (%) | 5.26 | 36.75 | 7.78 | 9.69 | 4.20 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis